Advances in Clinical Chemistry, Volume 112 highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Heterogeneity in Major Depressive Disorder: The need for Biomarker-based and Personalized Treatments, Advances in exosome analysis, Translational Proteomics and Phosphoproteomics: Tissue to Extracellular Vesicles, Immune Checkpoint Therapy, Tumor Immunology, and Biomarkers in Non-Small-Cell Lung Cancer, Advances in Congestive Heart Failure Biomarkers, Fluid biomarkers in Alzheimer’s disease, and more.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments - p. 1 8. Chapter Two: Advances in exosome analysis - p. 88 9. Chapter Three: Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles - p. 119 10. Chapter Four: Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers - p. 188 11. Chapter Five: Advances in congestive heart failure biomarkers - p. 205 12. Chapter Six: Fluid biomarkers in Alzheimer's disease - p. 249 13. Index - p. 281
Advances in Clinical Chemistry, Volume 112 highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Heterogeneity in Major Depressive Disorder: The need for Biomarker-based and Personalized Treatments, Advances in exosome analysis, Translational Proteomics and Phosphoproteomics: Tissue to Extracellular Vesicles, Immune Checkpoint Therapy, Tumor Immunology, and Biomarkers in Non-Small-Cell Lung Cancer, Advances in Congestive Heart Failure Biomarkers, Fluid biomarkers in Alzheimer’s disease, and more.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments - p. 1 8. Chapter Two: Advances in exosome analysis - p. 88 9. Chapter Three: Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles - p. 119 10. Chapter Four: Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers - p. 188 11. Chapter Five: Advances in congestive heart failure biomarkers - p. 205 12. Chapter Six: Fluid biomarkers in Alzheimer's disease - p. 249 13. Index - p. 281
